| Substance | Relationship Strength | Studies | Trials | Classes | Roles |
|---|
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth. | 2.07 | 1 | 0 | nucleobase analogue;
organofluorine compound | antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic |
os-4742a(1)
vineomycin A1: from Streptomyces strain No. 1894; structure in second source | 2.08 | 1 | 0 | | |
saquayamycin
saquayamycin: isolated from Streptomyces nodosus MH190-16F3; structure given in first source | 2.21 | 1 | 0 | | |
tetrangomycin
tetrangomycin: RN given for (+)-isomer; structure in first source. tetrangomycin : An angucycline antibiotic that is 3,4-dihydrotetraphene-1,7,12(2H)-trione substituted by hydroxy groups at positions 3 and 8 and a methyl group at position 3 (the 3R stereoisomer) ring system. It is an antibiotic isolated from Streptomyces sp. | 2.08 | 1 | 0 | | |
galtamycin
galtamycin: isolated from Streptomyces species; shows low antitumor activity; inactive against fungi and gram-positive and gram-negative bacteria | 2.21 | 1 | 0 | | |
rabelomycin
rabelomycin: structure | 2.17 | 1 | 0 | | |
dactinomycin
Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015) | 2.17 | 1 | 0 | actinomycin | mutagen |
glycosides
[no description available] | 2.21 | 1 | 0 | | |
rhodinose
rhodinose: structure in first source | 7.08 | 1 | 0 | trideoxyhexose | |
saquayamycin b
saquayamycin B: isolated from Streptomyces nodosus MH190-16F3; structure given in first source | 2.21 | 1 | 0 | | |